Brief: Savara Announces Expanded Access Program For Molgramostim Inhalation Solution For Patients With Autoimmune Pulmonary Alveolar Proteinosis

Savara

27/09/2024 13:07

Sept 27 (Reuters) - Savara Inc  SVRA.O :
    * SAVARA ANNOUNCES EXPANDED ACCESS PROGRAM (EAP) FOR
MOLGRAMOSTIM
INHALATION SOLUTION (MOLGRAMOSTIM) FOR PATIENTS WITH AUTOIMMUNE
PULMONARY ALVEOLAR PROTEINOSIS (APAP)
    * SAVARA :  SAVARA EARLY ACCESS ACCEPTING REQUESTS FROM
PATIENTS
IN SELECT COUNTRIES IN N.AMERICA & EUROPE, PLANS TO EXPAND
THROUGH 2026
    * SAVARA INC:  PLANS TO COMPLETE SUBMISSION OF A BLA TO FDA
FOR
MOLGRAMOSTIM IN APAP IN H1 OF 2025

Source text for Eikon:  ID:nBw2Xp2qna 
Further company coverage:  SVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))